BR112012027543A2 - formulações de quinonas para tratamento de doenças oftálmicas - Google Patents
formulações de quinonas para tratamento de doenças oftálmicasInfo
- Publication number
- BR112012027543A2 BR112012027543A2 BR112012027543A BR112012027543A BR112012027543A2 BR 112012027543 A2 BR112012027543 A2 BR 112012027543A2 BR 112012027543 A BR112012027543 A BR 112012027543A BR 112012027543 A BR112012027543 A BR 112012027543A BR 112012027543 A2 BR112012027543 A2 BR 112012027543A2
- Authority
- BR
- Brazil
- Prior art keywords
- quinone
- formulations
- quinones
- formulation
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
formulações de quinonas para o tratamento de doenças oftálmicas. uma formulação compreendendo uma quantidade oftalmicamente efetiva de uma ou mais quinonas de fórmula i. uso de uma formulação compreendendo uma ou mais quinonas de fórmula i para a prevenção, redução, melhora ou tratamento de distúrbios oftálmicos que são associados com um distúrbio de trauma ou neurodegenerativo também é discutido. um processo de tratamento ou controle de sintomas oculares associados com doenças neurodegenerativas ou trauma com uma formulação compreendendo uma ou mais quinonas de fórmula i também é discutido. um processo de tratamento ou controle de sintomas associados com miopatias mitocondriais com uma formulação compreendendo uma ou mais quinonas de fórmula i também é discutido.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32854610P | 2010-04-27 | 2010-04-27 | |
US39369310P | 2010-10-15 | 2010-10-15 | |
PCT/US2011/033983 WO2011137126A1 (en) | 2010-04-27 | 2011-04-26 | Formulations of quinones for the treatment of ophthalmic diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112012027543A2 true BR112012027543A2 (pt) | 2019-05-28 |
BR112012027543A8 BR112012027543A8 (pt) | 2019-12-03 |
Family
ID=44861894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012027543A BR112012027543A8 (pt) | 2010-04-27 | 2011-04-26 | formulações de quinonas para tratamento de doenças oftálmicas |
Country Status (13)
Country | Link |
---|---|
US (2) | US20130109759A1 (pt) |
EP (1) | EP2563352A4 (pt) |
JP (2) | JP5902673B2 (pt) |
CN (2) | CN105147651A (pt) |
AU (1) | AU2011245384C1 (pt) |
BR (1) | BR112012027543A8 (pt) |
CA (1) | CA2797581A1 (pt) |
EA (1) | EA201201465A1 (pt) |
MX (1) | MX337594B (pt) |
MY (1) | MY183449A (pt) |
SG (2) | SG185046A1 (pt) |
WO (1) | WO2011137126A1 (pt) |
ZA (1) | ZA201208535B (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
ES2619303T3 (es) | 2005-06-01 | 2017-06-26 | Edison Pharmaceuticals, Inc. | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
HUE028502T2 (en) | 2007-11-06 | 2016-12-28 | Edison Pharmaceuticals Inc | 4- (P-Quinonyl) -2-hydroxybutanamide derivatives for the treatment of mitochondrial diseases |
US8952071B2 (en) * | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
CA2717734A1 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases |
WO2009158348A1 (en) | 2008-06-25 | 2009-12-30 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
LT3827815T (lt) | 2008-09-10 | 2023-10-10 | Ptc Therapeutics, Inc. | Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais |
US10039722B2 (en) | 2008-10-14 | 2018-08-07 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
HUE041714T2 (hu) | 2008-10-28 | 2019-05-28 | Bioelectron Tech Corp | Kompozíció, amely tartalmaz alfa tokotrienolkinont és annak intermediereit |
DK2424495T3 (en) | 2009-04-28 | 2018-04-30 | Bioelectron Tech Corp | TREATMENT OF LEVERS HEREDIC OPTICAL NEUROPATHY AND DOMINANT OPTICAL ATROPHY WITH TOCOTRIENOL QUINONES |
HUE037592T2 (hu) * | 2009-08-26 | 2018-09-28 | Bioelectron Tech Corp | Eljárások cerebrális ischemia megelõzésére és kezelésére |
JP2013523816A (ja) * | 2010-04-06 | 2013-06-17 | エジソン ファーマシューティカルズ, インコーポレイテッド | 毛細血管拡張性運動失調症の治療 |
MX337594B (es) * | 2010-04-27 | 2016-03-11 | Edison Pharmaceuticals Inc | Formulaciones de quinonas para tratamiento de padecimientos oftalmicos. |
EP2720689A4 (en) | 2011-06-14 | 2014-11-26 | Edison Pharmaceuticals Inc | CATÉCHOL DERIVATIVES FOR THE TREATMENT OF OXIDATIVE STRESS DISEASES |
JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ, インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
JP6393684B2 (ja) * | 2012-09-07 | 2018-09-19 | バイオエレクトロン テクノロジー コーポレイション | 個体のレドックス状態の調節において使用するためのキノン誘導体 |
US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
CA2971252A1 (en) | 2014-12-16 | 2016-06-23 | Bioelectron Technology Corporation | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
US10745371B2 (en) | 2015-12-16 | 2020-08-18 | Ptc Therapeutics, Inc. | Methods for enriching alpha-tocotrienol from mixed tocol compositions |
AU2016369616B2 (en) | 2015-12-17 | 2021-03-25 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩 |
WO2019070917A1 (en) * | 2017-10-03 | 2019-04-11 | The Schepens Eye Research Institute, Inc. | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME |
ES2968957T3 (es) | 2018-10-17 | 2024-05-14 | Ptc Therapeutics Inc | 2,3,5-trimetil-6-nonilciclohexa-2,5-dieno-1,4-diona para la supresión y el tratamiento de alfa-sinucleinopatías, taupatías y otros trastornos |
US11786486B2 (en) | 2021-07-08 | 2023-10-17 | Ptc Therapeutics, Inc. | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2619303T3 (es) * | 2005-06-01 | 2017-06-26 | Edison Pharmaceuticals, Inc. | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
WO2007037849A2 (en) * | 2005-09-16 | 2007-04-05 | Allergan, Inc. | Compositions and methods for the intraocular transport of therapeutic agents |
EP1986636B1 (en) * | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
LT3827815T (lt) * | 2008-09-10 | 2023-10-10 | Ptc Therapeutics, Inc. | Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais |
HUE037592T2 (hu) * | 2009-08-26 | 2018-09-28 | Bioelectron Tech Corp | Eljárások cerebrális ischemia megelõzésére és kezelésére |
JP2013523816A (ja) * | 2010-04-06 | 2013-06-17 | エジソン ファーマシューティカルズ, インコーポレイテッド | 毛細血管拡張性運動失調症の治療 |
MX337594B (es) * | 2010-04-27 | 2016-03-11 | Edison Pharmaceuticals Inc | Formulaciones de quinonas para tratamiento de padecimientos oftalmicos. |
-
2011
- 2011-04-26 MX MX2012012518A patent/MX337594B/es active IP Right Grant
- 2011-04-26 BR BR112012027543A patent/BR112012027543A8/pt not_active IP Right Cessation
- 2011-04-26 JP JP2013508167A patent/JP5902673B2/ja not_active Expired - Fee Related
- 2011-04-26 MY MYPI2012004738A patent/MY183449A/en unknown
- 2011-04-26 CN CN201510490746.XA patent/CN105147651A/zh active Pending
- 2011-04-26 EA EA201201465A patent/EA201201465A1/ru unknown
- 2011-04-26 SG SG2012079323A patent/SG185046A1/en unknown
- 2011-04-26 CN CN2011800317444A patent/CN102985083A/zh active Pending
- 2011-04-26 AU AU2011245384A patent/AU2011245384C1/en not_active Ceased
- 2011-04-26 WO PCT/US2011/033983 patent/WO2011137126A1/en active Application Filing
- 2011-04-26 CA CA2797581A patent/CA2797581A1/en not_active Abandoned
- 2011-04-26 US US13/643,542 patent/US20130109759A1/en not_active Abandoned
- 2011-04-26 EP EP11775506.6A patent/EP2563352A4/en not_active Withdrawn
- 2011-04-26 SG SG10201801321XA patent/SG10201801321XA/en unknown
-
2012
- 2012-11-13 ZA ZA2012/08535A patent/ZA201208535B/en unknown
-
2016
- 2016-03-10 JP JP2016046881A patent/JP6266674B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-17 US US15/407,831 patent/US20170354618A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MY183449A (en) | 2021-02-18 |
CN102985083A (zh) | 2013-03-20 |
AU2011245384B2 (en) | 2016-02-18 |
US20170354618A1 (en) | 2017-12-14 |
CA2797581A1 (en) | 2011-11-03 |
MX337594B (es) | 2016-03-11 |
US20130109759A1 (en) | 2013-05-02 |
AU2011245384A1 (en) | 2012-12-06 |
SG10201801321XA (en) | 2018-04-27 |
JP6266674B2 (ja) | 2018-01-24 |
JP2013525443A (ja) | 2013-06-20 |
ZA201208535B (en) | 2016-06-29 |
BR112012027543A8 (pt) | 2019-12-03 |
EP2563352A4 (en) | 2013-11-13 |
EA201201465A1 (ru) | 2013-04-30 |
CN105147651A (zh) | 2015-12-16 |
EP2563352A1 (en) | 2013-03-06 |
JP2016106144A (ja) | 2016-06-16 |
JP5902673B2 (ja) | 2016-04-13 |
AU2011245384C1 (en) | 2016-09-01 |
MX2012012518A (es) | 2012-12-17 |
SG185046A1 (en) | 2012-12-28 |
WO2011137126A1 (en) | 2011-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012027543A8 (pt) | formulações de quinonas para tratamento de doenças oftálmicas | |
MX2011011310A (es) | Formulacion de tocotrienol quinonas para el tratamiento de enfermedades oftalmicas. | |
BR112015020050A2 (pt) | material óptico, composto para material óptico e sua utilização | |
BR112014026703A2 (pt) | inibidores de dna-pk | |
BR112015007778A2 (pt) | profármacos neutralizantes de vegf para o tratamento de condições oculares | |
BR112014024672A8 (pt) | Composições farmacêuticas para terapia de combinação | |
BR112015001847A2 (pt) | composições e tratamento para doenças e distúrbios nos olhos | |
BR112013019257A2 (pt) | composição de androgênio para tratar uma condição oftálmica | |
DOP2013000192A (es) | Compuestos y composiciones como inhibidores de la trk | |
BR112015003742A2 (pt) | sistema de montagem de componente de descarga | |
MY165124A (en) | Semifluorinated alkane compositions | |
MX2019003397A (es) | Metodos para tratar trastornos mitocondriales y metabolicos. | |
DOP2013000300A (es) | Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos | |
BR112016012840A2 (pt) | Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre | |
BR112017003745A2 (pt) | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico | |
BR112013022094A2 (pt) | composições e métodos para o tratamento não cirúrgico da ptose | |
BR112015009989A2 (pt) | estabilizante para a hialuronidase e formulação líquida que compreende hialuronidase | |
BR112017007025A2 (pt) | sulfatos de colesterol oxigenados para terapia de distúrbios causados por pelo menos um de atividade de leptina atenuada e um distúrbio de armazenamento de lipídio | |
BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
BR112012022074A2 (pt) | composição compreendendo como ingredientes ativos l-carnitina em combinação com hidroxiquinurenina-o-beta-dl-glicosídeo, para a prevenção e/ou tratamento de patologias dos olhos devido à radiação ultravioleta | |
BR112019007543A2 (pt) | inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase | |
BR112014017902A2 (pt) | Agente terapêutico ou profilático para doenças causadas por distúrbios do metabolismo de glicose | |
UY33568A (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
BR112015028516A2 (pt) | tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina | |
CR20160055A (es) | Composiciones tópicas para el tratamiento de sudoración excesiva y métodos para utilizar las mismas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: BIOELECTRON TECHNOLOGY CORPORATION (US) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2563 DE 2020-02-18 |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |